US M&A and equity raisings

3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

Deals dated after 30 September 2026 are still being collected.

Deal size
Custom range

36 deals · US$3.6bndisclosed · Pharma Services · Clear

Columns
US M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value US$m Sector Advisers
Sep 2026 Lifecore Biomedical –Webster Equity PartnersAcquisitionAnnounced663.7Pharma Services+2 Bourne Capital Partners (sell-side)Craig-Hallum (sell-side)Ballard Spahr (sell-side)Zukerman Gore Brandeis & Crossman (sell-side)Morgan Stanley (buy-side)Goodwin (buy-side)
Sep 2026 MLM Medical Labs –LabcorpAcquisitionAnnounced–Clinical Trial Services+1 William BlairEvercore (buy-side)Pierson Ferdinand (buy-side)Hogan Lovells Cadwalader (buy-side)
Sep 2026 New Zealand Clinical Research Group (NZCR) –AdventAcquisitionAnnounced–Clinical Trial Services Cameron Partners (buy-side)
Sep 2026 Ambit RD –Danforth HealthAcquisitionAnnounced–Pharma Services+1 Clearsight Advisors (sell-side)
Sep 2026 Firma Data Services Firma Clinical ResearchEverest Clinical ResearchAsset saleCompleted–Clinical Trial Services+1 Edgemont Partners (sell-side)
Sep 2026 Cellipont Bioservices ––MergerCompleted–Pharma Services+2 William Blair
Sep 2026 Prolytix EdgewaterVIONAcquisitionAnnounced–Pharma Services+1 Stout (sell-side)
Aug 2026 Precision Medicine Group BlackstoneMcKessonAcquisitionAnnounced2,250.0Clinical Trial Services+1 Debevoise & Plimpton (sell-side)Centerview Partners (sell-side)Davis Polk (buy-side)
Aug 2026 ZEPHYRx –a Leading Global CROAcquisitionCompleted–Healthcare Software+1 Morgan Lewis (sell-side)Edgemont Partners (sell-side)
Aug 2026 MAIN5 –AstrixAcquisitionAnnounced–Pharma Services+1 Gibson Dunn (buy-side)
Aug 2026 assets, business operations and customer relationships –NueCell BioAsset saleAnnounced–Pharma Services+1 Goodwin (buy-side)
Aug 2026 Relevate Health Mountaingate Capital–AcquisitionCompleted–Pharma Services+2 Latham & Watkins (sell-side)
Jul 2026 PANTHERx Rare Nautic PartnersWarburg Pincus-led investor groupAcquisitionAnnounced–Healthcare Services+2 Centerview Partners (sell-side)Goldman Sachs (sell-side)Ropes & Gray (sell-side)J.P. Morgan (buy-side)Cleary Gottlieb Steen & Hamilton (buy-side)
Jul 2026 Lannett –AurobindoAcquisitionCompleted250.0Pharma+1 Raymond JamesSullivan & Cromwell (buy-side)
Jul 2026 Commissioning Agents –JLL PartnersAcquisitionCompleted–Pharma Services+1 Stout (sell-side)
Jul 2026 OptiMed Health Partners –Lee Equity PartnersStakeCompleted–Pharma Services+1 Edgemont Partners (sell-side)
Jul 2026 Asembia –Peak Rock CapitalAcquisitionCompleted–Pharma Services+2 BofA Securities (sell-side)McDermott Will & Schulte (sell-side)Kirkland & Ellis (buy-side)Houlihan Lokey (buy-side)Bass, Berry & Sims (buy-side)
May 2026 AmbioPharm –CordenPharmaAcquisitionAnnounced–Pharma Services+2 Kirkland & EllisBNP Paribas (sell-side)Latham & Watkins (buy-side)
May 2026 MacroGenics GMP manufacturing site and CDMO operations MacroGenicsBora Pharmaceuticals Co.Asset saleCompleted122.5Pharmaceutical Manufacturing+1 Moelis & Company (sell-side)Sidley Austin (sell-side)Covington & Burling (sell-side)Jones Day (buy-side)
May 2026 CDMO and Cell Solutions businesses of Charles River Laboratories Charles River Laboratories InternationalGI PartnersAsset saleCompleted–Pharma Services+2 Moelis & Company (buy-side)Ropes & Gray (buy-side)
Apr 2026 Certara Regulatory and Medical Writing business CertaraVeristatAsset saleAnnounced135.0Pharma Services+1 Perella Weinberg Partners (sell-side)Troutman Pepper Locke (sell-side)Guggenheim Securities (buy-side)McDermott Will & Schulte (buy-side)
Apr 2026 EpiVax –SV Health InvestorsAcquisitionAnnounced–Pharma Services+2 Morgan Lewis (buy-side)
Apr 2026 Modersys (fka SmartFactory Rx) Applied MaterialsTELEO CapitalAsset saleCompleted–Industrial Software+1 Lazard
Apr 2026 Celerion H.I.G. Capital affiliateTHL PartnersAcquisitionAnnounced–Pharma Services+2 LazardKirkland & Ellis (buy-side)Paul, Weiss (buy-side)
Mar 2026 Syntegon CVC Capital PartnersApolloStakeAnnounced–Manufacturing+2 Willkie Farr & Gallagher (sell-side)Sidley Austin (buy-side)
Mar 2026 Owen Mumford Holdings –Embecta Corp.AcquisitionPending132.2Medtech+1 Forvis Mazars (South Africa) (sell-side)Mills & Reeve (sell-side)J.P. Morgan (buy-side)A&O Shearman (buy-side)
Mar 2026 Lonza Capsules & Health Ingredients division Lonza Group AGLone Star FundsAsset saleAnnounced–Pharmaceutical Manufacturing+2 Kirkland & Ellis (buy-side)
Mar 2026 Manufacturing facility in Phoenix, AZ Bristol Myers SquibbRoviAsset saleCompleted–Pharmaceutical Manufacturing+1 William Blair
Feb 2026 Laysan Bio –Gannet BioChemAcquisitionAnnounced–Pharma Services+2 Goodwin (buy-side)
Feb 2026 Broth –Supreme GroupAcquisitionAnnounced–Advertising and marketing+1 Edgemont Partners (sell-side)
Jan 2026 SubjectWell ––MergerAnnounced–Clinical Trial Services Stout (sell-side)Fairmount Partners (buy-side)
Jan 2026 Hayden Consulting Group –BGB GroupAcquisitionCompleted–Pharma Services+2 Morgan Lewis (sell-side)Clearsight Advisors (sell-side)
Jan 2026 Nivagen Pharmaceuticals –PAI PharmaAcquisitionAnnounced–Pharmaceutical Manufacturing+1 Bourne Partners (buy-side)Kirkland & Ellis (buy-side)KPMG (buy-side)
Jan 2026 Evidinno Outcomes Research –United BioSourceAcquisitionCompleted–Pharma Services+2 Fairmount Partners (sell-side)
Sep 2025 Zentiva Advent InternationalGTCRAcquisitionAnnounced–Pharma+1 Goldman Sachs (sell-side)PJT Partners (sell-side)Freshfields (sell-side)Barclays (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side)
Jun 2025 Felix Pharmaceuticals Pvt –Advent InternationalStakeAnnounced–Animal Health+2 A&L Goodbody LLPLincoln International (sell-side)Guggenheim Securities (buy-side)

Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built